Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosusSystemic lupus erythematosusdoi:10.1038/s41591-022-02091-9Andreas MackensenFabian MüllerDimitrios MougiakakosSebastian BltzArtur WilhelmMichael AignerSimon Vlkl...
12Long-lived plasma cells (LLPCs), enriched within the CD19–CD38hiCD138hiplasma cell subset, are an important source of autoantibody production in SLE.13The lack of CD19 in LLPCs raises questions about the applicability of CD19 CAR-T therapy in autoantibody-mediated autoimmune...
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study Article Open access 27 August 2024 Data availability Detailed data are available in the supplementary tables and figures published with this manuscript. Any materials generated during the...
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. PMID: 32894185 Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. PMID: 36453632 Cl...
3.Gauthier, J. et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies. Blood网页链接(2020). 4.Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, ...
A clinical trial for safety and efficient of CD19CART cells combination with nivolumab in the treatment of refractory/relapsed B cell lymphoma 开始日期2017-01-01 申办/合作机构- 100 项与Allogeneic anti-CD19 CAR-T (Tianjin First Center Hospital) 相关的临床结果 登录后查看更多信息 100 项与Allogenei...
CD19-targeting chimeric antigen receptor (CAR) T-cell therapy is a major breakthrough in the treatment of relapsed/refractory B-lineage malignancies, whose bystander effect is long-term B-cell aplasia.10 Consequently, these patients do not mount a humoral response after COVID-19 vaccination.11,...
Efficacy and toxicity of anti-CD19 CAR T-cells in patients with primary and secondary CNS-lymphoma – An analysis of the Lymphoma Working Party of the EBMT and the GoCART Coalition. Oral presentation at: EHA Meeting 2024; 2024 Jun 13; Vienna, Austria. EHA Library. Abstract 422392; S288. ...
英文标题:A phase I study of allogeneic anti-CD19 CAR-T therapy for patients with CD19+ relapsed/refractory acute B-lymphoblastic leukemia 中文标题:一项异基因抗CD19 CAR-T治疗CD19阳性复发/难治性急性B淋巴细胞白血病患者的Ⅰ期研究 汇报者:Sun Guangyu(中国科学技术大学附属第一医院) ...
Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. Howev